The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced.
The upcoming patent specifically covers methods to reduce clinical management events prior to and during Ponvory treatment, as well as methods for restarting the therapy after missed doses, according to a company press release.
When issued, the patent — number 17/962,968 — is expected to be valid until Oct. 10, 2042. Vanda will be listing the patent in the U.S. Food and Drug Administration’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” also known as the Orange Book. The cover of the nearly 2,000-page document is orange in color....read full article HERE.